SG Americas Securities LLC Sells 140,530 Shares of Recursion Pharmaceuticals, Inc. $RXRX

SG Americas Securities LLC lowered its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 90.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 14,701 shares of the company’s stock after selling 140,530 shares during the quarter. SG Americas Securities LLC’s holdings in Recursion Pharmaceuticals were worth $72,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Geode Capital Management LLC increased its position in Recursion Pharmaceuticals by 20.7% during the second quarter. Geode Capital Management LLC now owns 7,776,408 shares of the company’s stock valued at $39,353,000 after acquiring an additional 1,332,428 shares during the last quarter. Norges Bank purchased a new position in shares of Recursion Pharmaceuticals during the 2nd quarter worth about $16,040,000. First Trust Advisors LP grew its holdings in Recursion Pharmaceuticals by 82.3% during the 2nd quarter. First Trust Advisors LP now owns 1,880,290 shares of the company’s stock valued at $9,514,000 after purchasing an additional 848,791 shares during the last quarter. Bank Pictet & Cie Europe AG purchased a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $7,954,000. Finally, Vestmark Advisory Solutions Inc. lifted its stake in Recursion Pharmaceuticals by 89.6% in the second quarter. Vestmark Advisory Solutions Inc. now owns 1,339,139 shares of the company’s stock worth $6,776,000 after purchasing an additional 632,900 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RXRX has been the topic of a number of analyst reports. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. JPMorgan Chase & Co. raised shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. UBS Group set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average price target of $9.40.

Insider Activity at Recursion Pharmaceuticals

In related news, CFO Ben R. Taylor sold 21,383 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the transaction, the chief financial officer owned 761,550 shares of the company’s stock, valued at $3,183,279. The trade was a 2.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Najat Khan sold 124,403 shares of the stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $4.41, for a total value of $548,617.23. Following the sale, the insider directly owned 611,135 shares in the company, valued at $2,695,105.35. This trade represents a 16.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 585,786 shares of company stock valued at $2,558,598 over the last ninety days. 8.43% of the stock is owned by company insiders.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $4.19 on Friday. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36. The business has a 50-day moving average price of $4.50 and a 200 day moving average price of $4.99. The company has a market capitalization of $2.18 billion, a P/E ratio of -2.33 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.60 and a quick ratio of 4.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The business had revenue of $5.18 million for the quarter, compared to the consensus estimate of $19.36 million. During the same quarter last year, the firm posted ($0.34) EPS. The company’s revenue for the quarter was down 80.1% on a year-over-year basis. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.